Glaukos climbs as analysts lift targets, iDose TR label expansion stays in focus
Glaukos shares rose about 3% on April 6, 2026 as investors bid up the stock following recent analyst price-target increases after its Q4/FY 2025 results and upbeat 2026 net sales outlook of $600M–$620M. The move also reflects continued optimism around iDose TR momentum after the FDA cleared a labeling update allowing re-administration on January 28, 2026.
1) What’s moving the stock today
Glaukos (GKOS) was higher Monday, April 6, 2026, with the day’s strength tied to ongoing post-earnings bullishness: analysts have been lifting price targets following the company’s fourth-quarter and full-year 2025 report and its 2026 net sales outlook of $600 million to $620 million. That combination has kept sentiment constructive and helped support incremental buying on a modest up day.
2) The fundamental catalyst investors keep coming back to
Beyond near-term estimates, investors continue to focus on iDose TR as a long-duration glaucoma therapy and the impact of the FDA’s January 28, 2026 approval of an NDA labeling supplement that allows re-administration. The ability to repeat-dose broadens the practical treatment pathway for patients who need ongoing therapy over time, which the market views as supportive for longer-run demand and utilization.
3) What to watch next
Key swing factors are (a) evidence that iDose TR utilization expands as clinicians incorporate repeat dosing into real-world practice, (b) whether Glaukos can outperform or reiterate the $600–$620 million 2026 net sales range, and (c) progress on commercial execution for newer growth drivers referenced in company updates. Any additional price-target actions or incremental commercial milestones could amplify the stock’s day-to-day moves.